解析肝肿瘤异质性，改善健康公平性。
Dissecting liver tumor heterogeneity to improve health equity.
机构信息
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Trends Cancer. 2022 Apr;8(4):286-290. doi: 10.1016/j.trecan.2021.12.001. Epub 2022 Jan 7.
Abstract
Liver cancer burden varies greatly among populations. This disparity stems from the presence of complex etiology, sex, race/ethnicity, and extensive tumor molecular heterogeneity. Our ability to dissect tumor heterogeneity and to identify shared common features of liver cancer in diverse populations may improve precision medicine, thereby reducing disease burden.
摘要
肝癌的负担在不同人群中差异很大。这种差异源于复杂的病因、性别、种族/民族以及广泛的肿瘤分子异质性。我们能够剖析肿瘤异质性并识别不同人群中肝癌的共同特征，这可能会改善精准医学，从而降低疾病负担。
相似文献
1
Dissecting liver tumor heterogeneity to improve health equity.
Trends Cancer. 2022 Apr;8(4):286-290. doi: 10.1016/j.trecan.2021.12.001. Epub 2022 Jan 7.
2
Equity in Health: Consideration of Race and Ethnicity in Precision Medicine.
Trends Genet. 2020 Nov;36(11):807-809. doi: 10.1016/j.tig.2020.07.001. Epub 2020 Jul 22.
3
Heterogeneity of liver cancer and personalized therapy.
Cancer Lett. 2016 Sep 1;379(2):191-7. doi: 10.1016/j.canlet.2015.07.018. Epub 2015 Jul 23.
4
Precision models in hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):191-205. doi: 10.1038/s41575-024-01024-w. Epub 2024 Dec 11.
5
Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.
Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4.
6
How Can Law Support Development of Genomics and Precision Medicine to Advance Health Equity and Reduce Disparities?
Ethn Dis. 2019 Dec 12;29(Suppl 3):623-628. doi: 10.18865/ed.29.S3.623. eCollection 2019.
7
Precision diagnosis and treatment of liver cancer in China.
Cancer Lett. 2018 Jan 1;412:283-288. doi: 10.1016/j.canlet.2017.10.008. Epub 2017 Oct 16.
8
Launching Financial Incentives for Physician Groups to Improve Equity of Care by Patient Race and Ethnicity.
Milbank Q. 2024 Dec;102(4):944-972. doi: 10.1111/1468-0009.12720. Epub 2024 Oct 25.
9
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
J Hepatol. 2021 Mar;74(3):700-715. doi: 10.1016/j.jhep.2020.11.036. Epub 2020 Nov 30.
10
Health equity in the implementation of genomics and precision medicine: A public health imperative.
Genet Med. 2022 Aug;24(8):1630-1639. doi: 10.1016/j.gim.2022.04.009. Epub 2022 Apr 28.
引用本文的文献
1
Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer.
bioRxiv. 2025 Mar 12:2025.03.07.642107. doi: 10.1101/2025.03.07.642107.
2
Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer.
Mol Cell Biochem. 2025 Jan;480(1):1-17. doi: 10.1007/s11010-024-04983-5. Epub 2024 Mar 22.
3
Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases.
eGastroenterology. 2023 Oct;1(2). doi: 10.1136/egastro-2023-100020.
本文引用的文献
1
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
J Hepatol. 2021 Dec;75(6):1397-1408. doi: 10.1016/j.jhep.2021.06.028. Epub 2021 Jun 30.
2
Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry.
Oncotarget. 2021 Mar 2;12(5):475-492. doi: 10.18632/oncotarget.27890.
3
Genetic and non-genetic clonal diversity in cancer evolution.
Nat Rev Cancer. 2021 Jun;21(6):379-392. doi: 10.1038/s41568-021-00336-2. Epub 2021 Mar 16.
4
The genomic landscape of Mongolian hepatocellular carcinoma.
Nat Commun. 2020 Sep 1;11(1):4383. doi: 10.1038/s41467-020-18186-1.
5
Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma.
Gastroenterology. 2020 Dec;159(6):2203-2220.e14. doi: 10.1053/j.gastro.2020.08.015. Epub 2020 Aug 16.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Epidemiology and surveillance for hepatocellular carcinoma: New trends.
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.
8
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Cancer Cell. 2019 Oct 14;36(4):418-430.e6. doi: 10.1016/j.ccell.2019.08.007. Epub 2019 Oct 3.
9
Necroptosis microenvironment directs lineage commitment in liver cancer.
Nature. 2018 Oct;562(7725):69-75. doi: 10.1038/s41586-018-0519-y. Epub 2018 Sep 12.
10
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Cancer Cell. 2017 Jul 10;32(1):57-70.e3. doi: 10.1016/j.ccell.2017.05.009. Epub 2017 Jun 22.
Zotero 插件